Abstract 111P
Background
In China, fruquintinib is approved for third-line treatment of patients with metastatic colorectal cancer(mCRC). There are no prospective randomized controlled studies comparing the efficacy of fruquintinib and fruquintinib in combination with immune checkpoint inhibitors (ICIs). In this study, we aimed to compare the efficacy and safety of fruquintinib monotherapy versus combination with ICIs in MSS mCRC.
Methods
We retrospectively analyzed mCRC patients who received fruquintinib in Sun Yat-sen University Cancer Center from January 2020 to January 2022. The primary endpoints were overall survival (OS), progression-free survival (PFS) and adverse events. The secondary endpoints were objective remission rate (ORR) and disease control rate (DCR).
Results
A total of 184 patients with mCRC were included in this study, and 61 patients received ICIs combined with fruquintinib. Most patients received second line and above treatment before the study treatment. The ORR of fruquintinib combined with ICIs group (Group A, n=61) and fruquintinib group (Group B, n=123) were 14.3% and 3.6%; the DCR were 55.1% and 39.8%, respectively. Group A had a significant longer median PFS than Group B (3.9 months vs 3.3 months, P=0.015). However, the median OS was no significant difference between the two groups (mOS: 9.3 months vs 7.9 months, P=0.414). In the third line and above, there was no statistically significant difference in OS and PFS between the two groups. Multivariate analysis showed that baseline liver metastasis and lactate dehydrogenase (LDH)of≥313.3 were associated with shorter PFS in those 184 patients. Adverse effects of two groups were generally similar (91.8% vs 93.2%, P=0.738), and the most common adverse effects of two groups were the hand–foot skin reaction, hoarseness and hypertension. The probability of treatment-related adverse events (TRAEs)of grade 3 or higher was broadly similar in both groups (14.1% vs 14.6%, P=0.916).
Conclusions
In the real world, there was no difference in OS and in the incidence of adverse events between patients with MSS mCRC patients treated with fruquintinib monotherapy versus in combination with ICIs.
Clinical trial identification
NCT04005066.
Editorial acknowledgement
Legal entity responsible for the study
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract